Charles River Laboratories CRL
We began operating in 1947 and, since then, have undergone several changes to our business structure. 10-K, Item 1
- Employees
- 19,700
- Headquarters
- Wilmington, MA
- CEO
- Birgit Girshick
- Next results
- around Jan 12, 2027
CRL among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.
What changed
21 new risk paragraphs. 10-K filed Feb 18, 2026 against Feb 19, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 11 checks found nothing to note
-
Receivables -1.7% vs revenue -0.9% (-0.8 pts)
-
Cash from operations $737.6M vs net income −$144.3M (FY ending Dec 27, 2025)
-
Inventory +7.4% vs revenue -0.9% (+8.2 pts)
8 more checks with nothing to note
-
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Annual Goodwill Impairment Assessment - Biologics Solutions Reporting Unit; Revenue Recognition using the Cost-to-Cost Method - Discovery and Safety Assessment
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
21 paragraphs in Risk Factors that were not in the 10-K filed Feb 19, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
We leverage software and hardware solutions from technology and services providers, including software-as-a-service and public cloud infrastructure, who have been subject to cybersecurity incidents in the past and may have incidents or breaches in the future. As of the date of this filing, to our knowledge, no prior cybersecurity…
-
Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
Uncertainties with respect to the development, deployment, and use of artificial intelligence present new risks and challenges and could adversely affect our business and reputation. We, along with many businesses in the biopharmaceutical industry, are adopting and exploring the use of artificial intelligence (AI) in our business, and…
-
Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
Our review of potential strategic alternatives may not result in an executed or consummated transaction or other strategic alternative, and the process of reviewing strategic alternatives or the outcome could adversely affect our business. On May 6, 2025, in connection with a Cooperation Agreement entered into with a large shareholder…
-
Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
The EU GDPR also imposes specific restrictions on the transfer of personal data to countries outside of the EU and EEA, including the use of appropriate safeguards to enable such transfers, such as Standard Contractual Clauses (SCCs) and the EU-
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $4.0B | $4.1B | $4.0B | $4.0B |
| Net income | $486.2M | $474.6M | $22.2M | −$144.3M |
| Operating cash flow | $619.6M | $683.9M | $734.6M | $737.6M |
| Free cash flow | $294.9M | $365.4M | $501.6M | $518.5M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$4.0B ▼ 0.9% in FY2025−$144.3M in FY2025$518.5M ▲ 3.4% in FY2025
Recent filings
8 filings in the last 30 days · SEC EDGAR
-
8-KNov 9, 2026Regulation FD disclosure 8-K item 7.01
-
Planned saleNov 4, 2026Ms. Girshick (Chief Executive Officer) ended a 10b5-1 trading plan reported in the 10-Q, up to 10,814 shares, runs to Sep 1, 2027
-
Planned saleNov 4, 2026Nancy Andrews (directors) adopted a 10b5-1 trading plan reported in the 10-Q, up to 2,539 shares, runs to Nov 30, 2027
-
Planned saleNov 4, 2026Victoria Creamer (Chief People Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 12,996 shares, runs to Aug 31, 2027
-
8-KNov 4, 2026Quarterly results 8-K item 2.02
About the company
Charles River Laboratories, Wilmington, MA · from the 10-K filed Feb 18, 2026
We began operating in 1947 and, since then, have undergone several changes to our business structure. Charles River Laboratories International, Inc. was incorporated in 1994 and we completed our initial public offering in 2000. Our stock is traded on the New York Stock Exchange under the symbol “CRL” and is included in the Standard & Poor’s 500 and Composite 1500 indices, the New York Stock Exchange (NYSE) Arca Biotechnology Index, the NYSE Composite and many of the Russell indices, among others. We are headquartered in Wilmington, Massachusetts. Our headquarters mailing address is 251 Ballardvale Street, Wilmington, MA, 01887, and the telephone number at that location is (781) 222-6000.
- Headquarters
- Wilmington, MA
- Country
- United States
- Reports in
- USD
- Listed on
- NYSE
- Fiscal year ends
- December 27
- Last results
- Nov 4, 2026
Employees, at the top of the page: "As of December 27, 2025, we had approximately 19,700 employees (including approximately 2,400 science professionals with advanced degrees, including Ph" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 18, 2026 (open at SEC), compared with the 10-K filed Feb 19, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CRL/export.csv") into a cell.